ERCICEK, Fatma; HARSCOAT-SCHIAVO, Christelle; MARCHIVIE, Mathieu; MARRE, Samuel; SUBRA-PATERNAULT, Pascale

Métadonnées

Licence d’utilisation du document

ERCICEK, Fatma
Institut de Chimie de la Matière Condensée de Bordeaux [ICMCB]
Chimie et Biologie des Membranes et des Nanoobjets [CBMN]

HARSCOAT-SCHIAVO, Christelle
Chimie et Biologie des Membranes et des Nanoobjets [CBMN]

MARCHIVIE, Mathieu
Institut de Chimie de la Matière Condensée de Bordeaux [ICMCB]

Langue

Communication dans un congrès

Ce document a été publié dans

Proceedings 27th International Workshop on Industrial Crystallization, Proceedings 27th International Workshop on Industrial Crystallization, 2022-08-31, Espoo.

Résumé en anglais

Co-crystalline products are becoming increasingly important in the pharmaceutical industry, due to the chirality, low water solubility and low bioavailability of most active pharmaceutical ingredients (API). Solids with a single crystalline phase composed of two entities (API + coformer COF) linked via non-covalent interactions are called co-crystals. The modification of the API crystal lattice through the incorporation of the COF enhances the physicochemical properties of the initial drug without altering its therapeutic purposes. Thus, understanding crystallization processes can help to obtain products with desired properties. The formation of metastable conglomerates by co-crystallization can be a solution for optical resolution< Réduire

Mots clés en anglais

Co-crystallization

Supercritical CO2

Chiral resolution

In-situ observations

Microfluidics

Project ANR

Apport du CO2 dans le contrôle de phase cristalline - ANR-18-CE07-0047

Origine

Importé de hal

Unités de recherche

Institut de Chimie de la Matière Condensée de Bordeaux (ICMCB) - UMR 5026